SEC Filing Analysis: Vaxart, Inc. (VXRT)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Raquel C. Bono received a routine initial/annual equity compensation grant consisting of 78,800 restricted stock units and 157,400 stock options.
• Market Impact: Neutral; routine compensation with negligible market and dilution effects.

Company Information

Field	Value
Company	Vaxart, Inc.
Ticker Symbol	VXRT
CIK	0000072444
Industry	Biological Products (No Diagnostic Substances)

Insider Information

Field	Value
Name	Bono Raquel C.
CIK	0001823759
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-10-16
Transaction Code	A (Award/Grant)
Security Type	Common Stock
Shares Involved	78,800
Price Per Share	$0.00
Total Value	$0.00
Shares Owned After	78,800
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap	0.00%
Shares Transacted	78,800
% of Shares Outstanding	0.033%
Post-Transaction Ownership	78,800 shares (0.033% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of ~$110 million, an unpriced award of 78,800 shares represents less than $36,000 at the option strike price of $0.4527.
• Ownership Concentration: Insider ownership remains well below 0.1% of the company's 241,970,000 shares outstanding.
• Dilution Impact: Minimal. The combined 236,200 underlying shares (RSUs plus options) account for less than 0.10% total potential dilution.
• Transaction Significance: Routine director compensation; non-event for institutional valuation.

Market Impact Analysis

• Stock Impact Prediction: Neutral. Routine board equity grant with zero open-market cash outlay.
• Expected Volume Impact: Negligible. Shares vest over a three-year period subject to continuing service.
• Sentiment Indicator: Neutral.

Additional Context

• Transaction Notes: The RSUs and stock options vest in equal installments over the first three anniversaries of the grant date (October 16, 2026), contingent on continued board service.